Endo deals with FDA everyday Something completely odd here. I can understand small errors in judgement but there are multiple people involved with carrying this study forward it took this long to figure out theres not enough patients. Thats a load of bs, something else is up, information has to be given investors in a timely manner. If they knew months ago then there in trouble if anyone from either company sold a share. Hopefully they have altered the study and can use the data from it but I find it highly unlikely that this was from low numbers of patient enrolment does not add up at all. Endo is going to string us along for 10 years until the 100 million is worth nothing. Hopefully some kind of logical answer comes out soon, this is beyond belief at this point. That would be a very expensive mistake for Endo. I guess we will know soon if the burn rate drops five million a year from the pointe claire facility that is producing urocidin. Theres a good question for the AGM We should see the burn rate drop $1.25 Million per quarter now if we are shelving the trial for now?
JASL